Menu
Not yet recruiting NCT05477251

Comparative Study on the Efficacy and Safety of Microwave Ablation and Lobectomy in the Treatment of Ground Glass Nodules Located in the Pulmonary Hilar Region

No phase Interventional Pulmonary Nodule, Multiple Pulmonary Nodule, Solitary

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: microwave ablation, lobectomy.
Who it may be relevant to
Registry conditions: Pulmonary Nodule, Multiple, Pulmonary Nodule, Solitary. Basic parameters: 18 years — 75 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
Center list to be confirmed — check the primary protocol.
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Unsure about the terms? Read our patient guide →

Overview

GGO is a characteristic focus of early lung cancer. Due to the abundant peripheral blood vessels and bronchial tissues around the GGO lesions located in pulmonary hilar, only lobectomy could be used for the surgical treat of hilar GGO lesions which will make the significantly decline of the pulmonary function after surgery and affect the quality of life to a great extent. Our previous study has reported a new blunt-tip MWA electrode (MTC-3CA-II3, Vison Medical Inc.) for the treatment of GGO lesions. The blunt-tip MWA electrode could improve the safety of GGO ablation, significantly reduce the occurrence of bleeding and hemoptysis, which made it possible to ablate GGO in the hilar region safely. In this study, the blunt-tip MWA electrode was used in the treatment of patients with hilar GGO lesions, and the efficacy and safety of microwave ablation and lobectomy in the treatment of ground glass nodules located in the pulmonary hilar region were evaluated and compared.

Interventions

  • Procedure microwave ablation
    MWA procedures were performed under local anesthesia and CT guidance (GE Discovery CT750 HD) was used for the guidance. Using the coaxial system, MWA was performed by the combining of a 17G sharp-tip guide trocar needle and a 15-cm cooled-shaft electrode (18-gauge) with a 1.5-cm expandable blunt-tip (MTC-3CA-II3, Vison Medical Inc.). Firstly, the sharp-tip guide trocar needle was used to puncture through the pleura and then the blunt-tip MWA electrode was advanced into the GGO lesion through the
  • Procedure lobectomy
    lobectomy for GGOs located in hilar regions

Primary outcome measures

  • 3-year recurrence-free survival rate [Time frame: 3 year after treatment]
Secondary outcome measures (3)
  • Postoperative hospital stay [Time frame: During hospitalization]
  • Total hospitalization expenses Total hospitalization expenses [Time frame: During hospitalization]
  • Incidence of complications [Time frame: Within 1 month after operation]

Eligibility criteria

Inclusion criteria

  • The age ranged from 18 to 75 years old, male or female;
  • GGO lesions in the hilar region were diagnosed by imaging examination (CT / PET-CT). During the follow-up of 6-12 months, the lesions increased by more than 2mm, the solid components increased, or there were obvious solid components, or the GGOs were judged to be highly malignant by imaging.
  • The size of GGO lesions was 8mm-3cm, and the number of nodules was ≤ 3.
  • There was no lymph node metastasis, intrapulmonary metastasis or distant organ metastasis;
  • After multidisciplinary evaluation, the patients were feasible for lobectomy and CT guided microwave treatment;
  • No bleeding tendency, normal coagulation function or coagulation dysfunction can be corrected after treatment;
  • Patients and /or family members agreed to join the clinical trial and signed informed consent.

Exclusion criteria

  • The general condition of the patient is very poor, ECOG physical fitness score > 2, unable to tolerate lobectomy and MWA treatment, or has relevant contraindications;
  • The lesions had received other treatments before; patients with regional lymph node metastasis or distant metastasis or with pleural fluid and ascites;
  • Patients with poor compliance;
  • Severe heart, lung, kidney, brain and other important organ diseases;
  • The researcher believes that it is not suitable for inclusion

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation
Non-randomized
Model
Parallel assignment
Masking
Open label
Primary purpose
Treatment

Study locations

Center list to be confirmed — check the primary protocol.

Identifiers

NCT: NCT05477251 · KY2021-263-B

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗